Recommended Timeline for Oral Prednisolone in Active Ulcerative Colitis
For moderate to severe active ulcerative colitis, initiate prednisolone at 40 mg daily as a single dose and taper over 6-8 weeks, with treatment response assessed at 2 weeks to determine need for escalation. 1, 2
Initiation Protocol
Starting Dose
- 40 mg prednisolone daily is the evidence-based standard dose 1, 2
- Single daily dosing is as effective as split-dosing and causes less adrenal suppression 1
- Doses above 40-60 mg/day provide no additional benefit and increase adverse effects 1, 2
- Doses below 40 mg (e.g., 20 mg) are less effective 1, 2
When to Initiate
- First-line therapy for moderate to severe UC 1, 3
- Second-line therapy for mild to moderate UC failing 5-ASA after 2-4 weeks 2, 3, 2
- Should be combined with 5-ASA therapy 2
Critical Assessment Timeline
2-Week Checkpoint (Most Important)
Patients not responding after 2 weeks should be considered for treatment escalation to biologics or hospital admission 1. This is based on evidence showing:
- Improvements in clinical and endoscopic disease activity may be seen within 2 weeks 1
- Prolonging high-dose oral corticosteroids beyond this point has diminishing chance of achieving remission 1
- Continued steroid exposure increases risk of infective, metabolic, and surgical complications 1
Red Flags Requiring Immediate Escalation
Admit for inpatient management if patient develops:
- Fever
- Severe pain
- Significant anemia
- Generally unwell or not tolerating symptoms
- Systemic symptoms per Truelove and Witts criteria 1
Tapering Protocol
Standard Taper Duration
Taper over 6-8 weeks 1, 2, 1. This is a strong recommendation based on high-quality evidence from the most recent BSG guidelines.
Practical Tapering Approach
While specific tapering schedules vary, the evidence supports:
- Most commonly: reduce by 5 mg/week 4
- Avoid too rapid reduction, which associates with early relapse 5
- Doses below 15 mg/day are ineffective for active disease 5
- Disease relapse as dose reduces below 15 mg indicates need for steroid-sparing therapy 5
Treatment Escalation Criteria
When to Add Steroid-Sparing Agents
Consider thiopurines, anti-TNF therapy, vedolizumab, or tofacitinib if patient:
- Required 2 or more corticosteroid courses within past year 1
- Becomes corticosteroid-dependent (disease relapses as dose reduced below 15 mg) 5
- Becomes corticosteroid-refractory (no adequate response within 2 weeks) 1, 2
- Experiences unsuccessful corticosteroid taper 2
- Relapses within 6 weeks of stopping steroids 5
Common Pitfalls to Avoid
Prolonging high-dose steroids beyond 2 weeks without response - This increases complications without improving outcomes 1
Using steroids for maintenance therapy - Corticosteroids have no role in maintenance and should not be continued long-term 2, 5, 2, 5
Tapering too rapidly - Associated with early relapse 5
Using inadequate initial doses - Doses below 40 mg are less effective 1, 2
Failing to plan for steroid-free maintenance - After achieving remission, continue 5-ASA (at least 2 g/day) or consider steroid-sparing agents for maintenance 1, 2, 3
Safety Considerations
Approximately 50% of patients experience short-term corticosteroid-related adverse events including acne, edema, sleep and mood disturbance, glucose intolerance, and dyspepsia 1. The 2-week assessment point and 6-8 week taper duration balance efficacy against these risks while minimizing long-term complications including the 22% risk of steroid-dependence at 1 year 1.